This company listing is no longer active
C6O Stock Overview
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Clovis Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.023 |
| 52 Week High | €2.46 |
| 52 Week Low | €0.01 |
| Beta | 0.66 |
| 11 Month Change | 130.00% |
| 3 Month Change | -16.06% |
| 1 Year Change | -99.07% |
| 33 Year Change | -99.60% |
| 5 Year Change | -99.94% |
| Change since IPO | -99.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| C6O | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 53.3% | 0.8% | 0.8% |
| 1Y | -99.1% | -18.3% | 8.6% |
Return vs Industry: C6O underperformed the German Biotechs industry which returned -6.5% over the past year.
Return vs Market: C6O underperformed the German Market which returned 7.1% over the past year.
Price Volatility
| C6O volatility | |
|---|---|
| C6O Average Weekly Movement | 104.6% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: C6O's share price has been volatile over the past 3 months.
Volatility Over Time: C6O's weekly volatility has increased from 91% to 105% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 413 | Patrick Mahaffy | www.clovisoncology.com |
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, as well as for metastatic castration-resistant prostate cancer. In Europe, the company offers Rubraca for recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Clovis Oncology, Inc. Fundamentals Summary
| C6O fundamental statistics | |
|---|---|
| Market cap | €2.18m |
| Earnings (TTM) | -€226.19m |
| Revenue (TTM) | €119.44m |
0.0x
P/S Ratio0.0x
P/E RatioIs C6O overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| C6O income statement (TTM) | |
|---|---|
| Revenue | US$133.02m |
| Cost of Revenue | US$31.59m |
| Gross Profit | US$101.43m |
| Other Expenses | US$353.33m |
| Earnings | -US$251.91m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.73 |
| Gross Margin | 76.25% |
| Net Profit Margin | -189.37% |
| Debt/Equity Ratio | -158.0% |
How did C6O perform over the long term?
See historical performance and comparison